Zwyrodnienie korowo-podstawne (zespół korowo-podstawny)
Epidemiologia

Zwyrodnienie korowo-podstawne (CBD) to rzadkie, postępujące zaburzenie neurodegeneracyjne, charakteryzujące się zanikiem obszarów mózgu odpowiedzialnych za przetwarzanie informacji i kontrolę ruchu. Zachorowalność na CBD wynosi około 0,6-0,9 przypadków na 100 000 osób rocznie, a choroba stanowi 4-6% przypadków parkinsonizmu. Średni wiek wystąpienia objawów to około 64 lata, z typowym zakresem 50-70 lat, a średni czas przeżycia od wystąpienia symptomów wynosi 6-8 lat. Diagnostyka kliniczna jest trudna, z dokładnością rozpoznania przedśmiertnego na poziomie 25-56%, co wynika z klinicznej i patologicznej heterogeniczności oraz podobieństwa objawów do innych zaburzeń neurologicznych. Patologia CBD odpowiada za około 32% przypadków zespołu korowo-podstawnego (CBS), z pozostałymi przypadkami związanymi m.in. z postępującym porażeniem nadjądrowym (PSP) i chorobą Alzheimera.

  1. Zwyrodnienie korowo-podstawne (zespół korowo-podstawny) – Epidemiologia i nadzór
    1. Zachorowalność i chorobowość
    2. Wiek i płeć
    3. Przebieg choroby i przeżycie
    4. Rozpoznanie i diagnoza
    5. Czynniki ryzyka i genetyka
    6. Podtypy CBD/CBS
    7. Patologie leżące u podstaw CBS
    8. Biomarkery i diagnostyka
    9. Perspektywy i badania
    10. Kolejne rozdziały

Zwyrodnienie korowo-podstawne (zespół korowo-podstawny) – Epidemiologia i nadzór

Zwyrodnienie korowo-podstawne (ang. corticobasal degeneration – CBD) to rzadkie neurodegeneracyjne zaburzenie charakteryzujące się zanikiem obszarów mózgu przetwarzających informacje oraz struktur kontrolujących ruch. Najczęstszą manifestacją kliniczną CBD jest zespół korowo-podstawny (ang. corticobasal syndrome – CBS), który stanowi konstelację objawów korowych i pozapiramidowych. Ze względu na rzadkość występowania, dużą heterogenność kliniczno-patologiczną oraz brak ustalonych kryteriów diagnostycznych do niedawna, dane epidemiologiczne dotyczące CBD/CBS są ograniczone.123

Zachorowalność i chorobowość

Szacuje się, że CBD występuje około dziesięć razy rzadziej niż postępujące porażenie nadjądrowe (PSP). Zachorowalność (incydencja) na CBD szacowana jest na 0,6-0,9 przypadków na 100 000 osób rocznie, a choroba stanowi około 4-6% przypadków parkinsonizmu.12 Pojedyncze badania prognozują chorobowość (prevalence) na poziomie 4,9-7,3 przypadków na 100 000 osób, opierając się na danych dotyczących zachorowalności i średnim czasie przeżycia.123

Wyniki metaanalizy wykazały, że zachorowalność na CBS waha się od 0,03 do 0,8 przypadku na 100 000 osobolat, a chorobowość od 0,83 do 25 na 100 000 osób.12 Dodatkowe szacunki sugerują roczną zachorowalność na CBS na poziomie mniejszym niż 1 na 100 000 pacjentów, co opiera się na wynikach badań z Japonii i Rosji.1

Według Narodowej Organizacji ds. Rzadkich Chorób, CBS dotyczy około 5 osób na 100 000, z przybliżoną liczbą 62-92 nowych przypadków rocznie na 100 000 osób.1 Co ciekawe, w kohortowym badaniu obejmującym 120 000 osób nie opisano żadnego przypadku CBD, co wskazuje na trudności diagnostyczne i prawdopodobnie niedoszacowanie problemu.12

Całkowita liczba przypadków CBS w krajach G7 ma osiągnąć 60 000 do 2030 roku przy CAGR na poziomie 0,5%. Wśród nich CBD przyczynia się do największej liczby przypadków CBS, stanowiąc 45,5%.1

Wiek i płeć

Średni wiek wystąpienia objawów choroby wynosi około 64 lata, natomiast najmłodszy potwierdzony patologicznie przypadek odnotowano u osoby w wieku 43 lat.12 Typowy wiek zachorowania mieści się w przedziale od 50 do 70 lat, choć objawy mogą pojawić się już w wieku 40 lat. Nie odnotowano przypadków występowania choroby u osób poniżej 40. roku życia.123

W serii autopsji z CurePSP Brain Bank w Mayo Clinic (Jacksonville, Floryda) przebadano 76 przypadków patologicznie potwierdzonych CBD. Stwierdzono średni wiek śmierci wynoszący 70 ± 8,7 lat (zakres 46-89 lat), przy czym 53% przypadków stanowili mężczyźni.1

Jeśli chodzi o płeć, wyniki badań są niejednoznaczne. W kilku badaniach CBD zgłaszano jako częstsze u kobiet, jednak nowsze badania nie potwierdziły tego faktu.12 Niektóre analizy sugerują nieznaczną przewagę występowania u kobiet, podczas gdy inne wskazują na brak istotnych różnic między płciami.123

Przebieg choroby i przeżycie

CBD jest chorobą postępującą, powodującą narastający poziom niepełnosprawności i utratę niezależności. Średni czas przeżycia od momentu wystąpienia objawów szacowany jest na 6-8 lat, jednak odnotowano wiele przypadków przeżycia 10 lat i dłużej.1234 W badaniu autopsyjnym z Mayo Clinic oszacowano średni czas trwania choroby na 6 ± 2,3 lat.1

Osoby z CBD umierają zazwyczaj w ciągu 10 lat od wystąpienia objawów, z powodu powikłań dysfagii (zachłystowe zapalenie płuc), nietrzymania moczu (zakażenia dróg moczowych powikłane posocznicą) oraz unieruchomienia (podatność na zakażenia).123 Zgon w CBS jest najczęściej spowodowany zapaleniem płuc lub innymi powikłaniami, takimi jak posocznica lub zatorowość płucna.1

Rokowanie jest zmienne, a średnie przeżycie wynosi 6-8 lat od wystąpienia objawów, jednak jest to tylko średnia, a CBD jest bardzo zróżnicowane pod tym względem.12

Rozpoznanie i diagnoza

Dokładna wczesna diagnoza jest niezbędna, ponieważ może kierować opieką nad pacjentem i ułatwić opracowanie ukierunkowanych terapii i specyficznych dla choroby biomarkerów.1 CBS charakteryzuje się najniższą dokładnością diagnostyki klinicznej, przy czym najwyższą prezentację kliniczną stwierdza się w CBD.1

CBD jest trudne do zdiagnozowania przed śmiercią, ponieważ jego objawy są podobne do objawów innych zaburzeń neurologicznych. Patologia CBD jest prawidłowo przewidywana tylko w 25-56% przypadków przed autopsją.12

Diagnoza CBS opiera się na obecności określonych cech klinicznych, a ostateczne potwierdzenie wymaga badania patologicznego po śmierci. W celu diagnozy wykorzystuje się obecnie kryteria zaproponowane w 2013 roku przez Armstrong i wsp.123

Ponieważ CBD jest prawidłowo diagnozowane przed śmiercią tylko w 25-56% przypadków, dyskusje na temat ograniczeń bezpiecznego testowania czynników modyfikujących są istotne. Dlatego CBD wydaje się nie budzić zainteresowania większej liczby badań klinicznych ze względu na niską częstość występowania i niską wiarygodność diagnozy klinicznej.1

Czynniki ryzyka i genetyka

Jedynym dobrze ustalonym czynnikiem ryzyka CBD jest zaawansowany wiek.1 CBD jest uważane głównie za idiopatyczne lub sporadyczne zaburzenie neurodegeneracyjne, a przypadki rodzinne są niezwykle rzadkie.12

CBS jest generalnie uznawany za sporadyczne zaburzenie, chociaż opisano rzadkie przypadki rodzinne i izolowane przypadki genetyczne.12

CBD powiązano ze zmianami w określonych genach, ale te powiązania genetyczne są słabe, a ryzyko dla innych członków rodziny jest bardzo niskie.1 Jak dotąd zidentyfikowano dwa główne genetyczne czynniki ryzyka związane z CBS: homozygotyczność dla haplotypu MAPT H1c i MOBP (białko zasadowe oligodendrocytów związane z mieliną).1

W 70% przypadków rodzinnych CBS zgłaszano dodatni wywiad rodzinny w kierunku jednej z następujących chorób neurologicznych: CBS, choroba Parkinsona, otępienie czołowo-skroniowe lub niespecyficzne otępienie.1 Mutacja genu progranulinowego (GRN) jest najczęstszą przyczyną rodzinnego CBS.1

Identyfikacja wariantów genetycznych leżących u podstaw CBS ma duże praktyczne znaczenie, ponieważ umożliwia odpowiednie poradnictwo rodzinne i możliwość włączenia do badań klinicznych z leczeniem modyfikującym przebieg choroby.1

Podtypy CBD/CBS

Od 2013 roku eksperci CBD wyróżniają cztery główne typy CBD:

  • Zespół korowo-podstawny (CBS)
  • Zespół czołowo-behawioralno-przestrzenny (FBS)
  • Niepłynny/agramatyczny wariant pierwotnej postępującej afazji (naPPA)
  • Zespół postępującego porażenia nadjądrowego (PSPS)

1

Objawy tych czterech typów są tak różne, że wydają się być całkowicie różnymi zaburzeniami, co komplikuje diagnozę i badania epidemiologiczne.1

Patologie leżące u podstaw CBS

Heterogeniczność patologiczna leżąca u podstaw CBS została zgłoszona w kilku seriach autopsji. CBD odpowiadało za mniej niż połowę pacjentów z CBS, podczas gdy PSP i choroba Alzheimera były najczęstszymi diagnozami patologicznymi innymi niż CBD.1

Najczęstszymi diagnozami patologicznymi były CBD (32%), następnie PSP (31%), choroba Alzheimera (20%) i inne (17%), w tym choroba Lewy’ego, otępienie czołowo-skroniowe z inkluzjami TDP, choroba neuronu ruchowego, choroba Picka, FTLD-FUS, choroba Creutzfeldta-Jakoba i choroba naczyniowa mózgu.1

Corticobasal degeneration (CBD) i Progressive Supranuclear Palsy (PSP) to dwa najczęstsze podłoża neuropatologiczne CBS, z których każde stanowi około jedną trzecią wszystkich przypadków.1

Biomarkery i diagnostyka

Biomarkery molekularne, które mogą wykrywać specyficzne białka patologiczne, rokują nadzieje na poprawę diagnoz przyżyciowych. Ponieważ ustalono kilka wiarygodnych biomarkerów dla choroby Alzheimera, praktycznym podejściem jest najpierw odróżnienie AD od innych zaburzeń.1

Badanie PET amyloidu zostało opracowane jako biomarker obrazowania do wizualizacji akumulacji amyloidu in vivo. Metaanaliza badań PET amyloidu wykazała, że 23 z 61 (38%) pacjentów z CBS wykazało pozytywny wynik amyloidu w badaniu PET. Co ciekawe, częstość dodatnich wyników amyloidu zmniejsza się z wiekiem.1

Po sukcesie PET amyloidu, białko tau stało się celem diagnostyki molekularnej in vivo. PET tau może pomóc odróżnić tauopatię-CBS od nietauopatii-CBS i AD-CBS od nietauopatii-AD; jednak pozostaje wyzwaniem odróżnienie nietauopatii-AD, szczególnie CBD i PSP.1

Obecnie do ostatecznej diagnozy wymagana jest ocena patologiczna, ale w przyszłości może być możliwe przewidywanie patologii leżącej u podstaw w ciągu życia, w oparciu o kombinację objawów klinicznych i oznak z informacjami wspierającymi z różnych biomarkerów.1

Integracja biomarkerów płynowych, testów genetycznych i wyników obrazowania może poprawić dokładność diagnostyczną w rutynowej praktyce klinicznej, identyfikując in vivo podstawowe procesy patologiczne i funkcje neuronalne, które najprawdopodobniej ulegną upośledzeniu w trakcie ewolucji choroby.1

Perspektywy i badania

Ponieważ starzenie się jest największym czynnikiem ryzyka dla atypowych zespołów parkinsonowskich, przewiduje się, że częstość występowania PSP i CBD będzie wzrastać w nadchodzących latach. Dlatego istnieje pilna potrzeba opracowania testów, które mogą diagnozować te zaburzenia wcześnie i dokładnie, oraz leczenia, które zatrzyma ich postęp, zanim staną się niepełnosprawne.1

Prowadzone są ważne badania mające na celu poszukiwanie genetycznych i środowiskowych czynników przyczyniających się do powstawania CBD, a także badania nad testami, które mogą prowadzić do dokładniejszej diagnozy i poprawy opieki nad CBD.1

Badania nad CBD koncentrują się na zrozumieniu jego patofizjologii, poprawie dokładności diagnostycznej i opracowaniu skutecznych metod leczenia. Badacze badają czynniki genetyczne, które mogą predysponować osoby do CBD, a także wpływy środowiskowe, które mogą wyzwalać jego początek.1

Obecne leczenie CBD pozostaje objawowe i opiera się na danych z innych podobnych chorób, takich jak choroba Parkinsona, choroba Alzheimera i otępienie czołowo-skroniowe, z powodu braku konkretnych badań dotyczących CBD.1

Trwają badania nad nowymi terapiami i metodami diagnostycznymi, co daje nadzieję osobom z tym schorzeniem i ich opiekunom.1

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 09.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Corticobasal degeneration and corticobasal syndrome: A review
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8288513/
    Corticobasal degeneration (CBD) is a rare neurodegenerative disorder. The most common presentation of CBD is the corticobasal syndrome (CBS), which is a constellation of cortical and extrapyramidal symptoms and signs. […] Robust epidemiological data on CBD are lacking because of the rarity of the disease, the great clinical pathological heterogeneity of the disorder and the lack of established criteria until recently. It is estimated that it is ten times rarer than progressive supranuclear palsy (PSP). Its’ incidence is estimated at 0.60.9/100,000/year and it represents 46% of patients with Parkinsonism. A single study projected a prevalence of 4.97.3 per 100.000, based on incidence and mean survival data. However, in a cohort of 120,000, no case of CBD was described. […] Mean age at disease onset is about 64years, whereas the youngest pathologically confirmed case was 43years old. There could be a slight female predominance. Mean survival is estimated at 6.5years.
  • #1 Corticobasal Degeneration | Treatment & Management | Point of Care
    https://www.statpearls.com/point-of-care/157387
    Results from a meta-analysis showed the incidence of CBS ranges from 0.03 to 0.8 per 100,000 person-years and its prevalence from 0.83 to 25 per 100,000. […] Additional estimates suggest an annual CBS incidence of less than 1 per 100,000 patients based on study results from Japan and Russia. […] While earlier reports indicated an annual CBD incidence of 0.6 to 0.9 per 100,000, representing 4% to 6% of Parkinsonian syndromes, and a prevalence of 4.9 to 7.3 per 100,000, results from a large United Kingdom cross-sectional study involving 121,608 patients did not identify any confirmed cases of CBD. […] The disease typically has a late onset, with the youngest pathologically confirmed case reported at 42 and an average age of onset around 65. […] An autopsy series from the CurePSP Brain Bank at the Mayo Clinic (Jacksonville, Florida) examined 76 cases of pathologically confirmed CBD. They found a mean age of death of 70 8.7 years (range 46-89 years), with 53% of the cases being men. The estimated average disease duration was 6 2.3 years. […] While results from some studies have suggested a higher prevalence of CBD in women, others have not demonstrated significant sex differences.
  • #1 Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032 – Mellalta Meets
    https://mellalta.com/product/corticobasal-syndrome-cbs-primary-research-kols-insight-market-intelligence-epidemiology-market-forecast-2032/
    Corticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). […] The total prevalent cases of Corticobasal syndrome (CBS) in the G7 countries is expected to reach 60,000 by 2030 at a CAGR of 0.5%. According to the National Organization for Rare Disorders, CBS tend to affect both males and females equally and usually, estimated to affect 5 people per 100,000, with approximately 62-92 new cases per year per 100,000 people. […] Among which, Corticobasal degeneration (CBD) contribute to the highest CBS cases by 45.5%.
  • #1 Corticobasal Degeneration (Corticobasal Syndrome): What It Is
    https://my.clevelandclinic.org/health/diseases/22522-corticobasal-degeneration
    Corticobasal degeneration (corticobasal syndrome) is a rare brain condition that causes you to lose your ability to speak, move and remember. Symptoms are progressive, so they slowly get worse over time. While there arent any treatments to slow or stop changes to your brain, therapies are available to help manage the condition. […] Corticobasal degeneration may shorten your life expectancy and lead to life-threatening complications. As symptoms affect more of your body, you may find it difficult to safely maintain your independence. […] Symptoms of corticobasal degeneration typically start between ages 50 and 70. The average onset age is 64. Symptoms may start at age 40, but no reported cases happen before age 40. […] The prognosis (outlook) is poor for corticobasal degeneration. Its a progressive disease, which means itll get worse over time. It usually happens slowly over many years. Your provider will offer treatment options to help you cope and manage symptoms. Treatment options may reduce the severity of symptoms, but it wont stop them from progressing. As symptoms get worse, itll be more challenging to maintain independence and take care of yourself.
  • #1 Corticobasal Syndrome and Corticobasal Degeneration: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/1150039-overview
    In several studies, CBD was reported to be more common in women. However, more recent studies have not found this to be the case. […] Typically, CBD presents between the ages of 50 and 75 years. The CBD cases from multiple brain banks reviewed as part of the Armstrong et al. diagnostic criteria had mean age of onset of 63 years with a standard deviation of 7 years and range of 4577 years. […] This is a progressive neurodegenerative disorder that causes increasing levels of disability and loss of independence. Individuals with CBD usually die within 10 years of symptom onset from complications of dysphagia (aspiration pneumonia), urinary incontinence (urinary tract infections complicated by urosepsis) and an immobile state (susceptibility to infections). […] Prognosis is variable, with several studies indicating mean survival of 68 years from symptom onset; multiple cases with survival of 10 years have been reported.
  • #1 Corticobasal Syndrome – Frontotemporal Degeneration | AFTD
    https://www.theaftd.org/what-is-ftd/corticobasal-syndrome/
    CBS is almost always sporadic, developing by chance rather than being inherited. […] Upon autopsy, corticobasal degeneration is characterized by nerve cell loss, gliosis and atrophy of the deeper layers in the posterior frontal and/or parietal lobes, and the substantia nigra. […] Corticobasal Syndrome usually progresses slowly over the course of 6 to 8 years. […] Death in CBS is generally caused by pneumonia or other complications, such as sepsis or pulmonary embolism.
  • #1
    https://www.nhs.uk/conditions/corticobasal-degeneration/
    Corticobasal degeneration (CBD) is a rare condition that can cause gradually worsening problems with movement, speech, memory and swallowing. […] Most cases of CBD develop in adults aged between 50 and 70. […] CBD has been linked to changes in certain genes, but these genetic links are weak and the risk to other family members is very low. […] There is currently no treatment that has been shown to stop CBD getting gradually worse, although treatments can reduce many of the symptoms. […] As a result of these complications, the average life expectancy for someone with CBD is around 6 to 8 years from when their symptoms start. However, this is only an average and CBD is very variable.
  • #1 Corticobasal Degeneration | Treatment & Management | Point of Care
    https://www.statpearls.com/point-of-care/157387
    Corticobasal degeneration (CBD) is a rare and progressive neurodegenerative disorder with diverse clinical and pathological features. The most common clinical presentation, corticobasal syndrome, includes asymmetric limb rigidity, Parkinsonism, dystonia, and cortical dysfunction, such as apraxia or sensory deficits. […] Accurate early diagnosis is essential, as it can guide patient care and facilitate the development of targeted therapies and disease-specific biomarkers. […] CBD is primarily considered an idiopathic or sporadic neurodegenerative disorder, with familial cases being exceedingly rare. […] The only well-established risk factor for CBD is advanced age. […] CBD is a neurodegenerative disorder characterized by complex pathological mechanisms and diverse clinical presentations, collectively referred to as clinicopathologic heterogeneity. This variability significantly hampers antemortem diagnosis and limits the ability to conduct robust epidemiological studies. Notably, CBD pathology is correctly predicted in only 25% to 56% of cases prior to autopsy.
  • #1 Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
    https://www.mdpi.com/2073-4409/10/1/171
    Corticobasal syndrome (CBS) is a rare neurological disorder characterized by a combination of asymmetric akinetic–rigid parkinsonism, fixed dystonic postures, pyramidal signs, and cognitive deficits, such as behavioral changes, speech and language alterations, apraxia, visuospatial impairment, and other cortical signs, including alien-limb phenomena, myoclonus, and cortical sensory loss. […] CBS has a reported prevalence of 4.9 to 7.3 cases per 100,000 individuals; symptoms usually appear between the fifth and the seventh decade of life, and death occurs within 6 or 7 years after the symptoms’ onset. […] Different diagnostic criteria for CBS have been proposed over time, including those advanced by Lang and Bergeron (Toronto), Boeve et al. (Mayo clinic), and Bak and Hodges (Cambridge), as well as the latest by Armstrong et al. in 2013.
  • #1 SciELO Brazil – Pharmacological interventions in corticobasal degeneration: a review Pharmacological interventions in corticobasal degeneration: a review
    https://www.scielo.br/j/dn/a/H9QPjg9FZdks9zWLsphZdHj/
    Corticobasal degeneration (CBD) is a sporadic tauopathy that presents with a varied combination of motor, cognitive, and behavioral features, making its diagnosis difficult. CBD has high morbidity and poor prognosis, with no effective therapy at present. […] CBD presents high morbidity and poor prognosis because of the lack of effective therapy at present. Treatment is symptomatic and based on features of other similar diseases due to the scarcity of studies focused on CBD. […] Given that CBD is correctly diagnosed before death only in 25-56% of cases, discussions about the limitations of safely testing modifying agents are pertinent. Therefore, CBD seems not to spark interest in a greater number of clinical trials due to its low prevalence and the low reliability of clinical diagnosis.
  • #1 Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
    https://www.mdpi.com/2073-4409/10/1/171
    CBS is generally recognized as a sporadic disorder, although rare familial and isolated genetic cases have been reported. […] The purpose of this paper is to review relevant publications describing cases of genetically determined CBS and to identify distinctive clinical features that may suggest the most likely associated genetic cause. […] We identified 40 publications fulfilling the inclusion criteria and collected information on 58 cases. […] GRN was the most common gene involved, with 28 cases (48%) from 23 families, followed by MAPT (16%), C9ORF72 (10%), and PRNP (7%). […] In 70% of the cases, a positive family history was reported for one of the following neurological diseases: CBS, Parkinson’s disease (PD), frontotemporal dementia (FTD), or non-specific dementia. […] So far, two major genetic risk factors have been found to be associated with CBS: homozygosity for the MAPT H1c haplotype and MOBP (myelin-associated oligodendrocyte basic protein). […] The H1 MAPT haplotype confers a higher risk of developing both PSP and CBS/CBD. […] Identifying genetic variants underlying CBS has a great practical relevance, since it allows appropriate family counseling and the possibility to be enrolled in clinical trials with disease-modifying treatments.
  • #1 Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review | Neurological Research and Practice | Full Text
    https://neurolrespract.biomedcentral.com/articles/10.1186/s42466-023-00294-0
    Corticobasal syndrome (CBS) is a clinical syndrome determined by various underlying neurodegenerative disorders requiring a pathological assessment for a definitive diagnosis. […] Corticobasal degeneration (CBD) and Progressive Supranuclear Palsy (PSP) are the two most common neuropathological substrates of CBS, each accounting for about one third of all cases. […] Sporadic presentations represent most CBS cases, but familial cases have been described as well: progranulin gene (GRN) mutation is the most common cause of familial CBS. […] Antemortem diagnosis relies on clinical criteria supported, to a limited extent, by ancillary investigations. […] Consequently, this biological heterogeneity collects several implications and repercussions: first, in the presence of an atypical clinical presentation, the differential diagnosis with other neurodegenerative disorders based on CSF findings and imaging biomarkers remains challenging, non-specific, and unreliable, raising considerable concerns on optimal patients management and counselling.
  • #1 Corticobasal Degeneration (CBD) – Brain Support Network
    https://www.brainsupportnetwork.org/education/corticobasal-degeneration/
    The symptoms of these four types are so different that they seem to be entirely different disorders. […] There is remarkably limited treatment for CBD/CBS. The most effective treatments are the therapies: physical therapy, occupational therapy, and speech therapy. Therapies are pinpointed on prevention of falls and aspiration pneumonia. […] The medication that can be prescribed and any other treatments are focused on a few symptoms that may respond to medication or treatments such as depression, urinary incontinence, and dry eyes. There is no evidence that any of the Parkinsons medications (levodopa therapy) or Alzheimers medications are helpful in CBD/CBS. […] The diagnostic criteria listed in this section are derived from the paper Criteria for the diagnosis of corticobasal degeneration, Armstrong, et al. published in Neurology in 2013. […] The paper explains CBD in terms of four distinct types (phenotypes) of the disease. These are: corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), nonfluent/agrammatic variant of primary progressive aphasia (naPPA), progressive supranuclear palsy syndrome (PSPS).
  • #1 Neuropathology and emerging biomarkers in corticobasal syndrome | Journal of Neurology, Neurosurgery & Psychiatry
    https://jnnp.bmj.com/content/93/9/919
    Heterogeneity of the underlying neuropathology associated with CBS has been reported in several autopsy series. […] CBD accounted for less than half of patients with CBS, while PSP and AD were the most common non-CBD pathological diagnoses. […] The most common pathological diagnoses were CBD (32%), followed by PSP (31%), AD (20%) and others (17%), including LBD, FTLD-TDP, motor neuron disease, Picks disease, FTLD-FUS, CJD and cerebrovascular disease. […] Recent advances in molecular biomarkers have greatly improved the accuracy of the clinical diagnosis of AD. […] It must be noted, however, that a clinical diagnosis of AD does not rule out other disease processes, such as CBD and PSP. […] A recent study from the Mayo Clinic brain bank reported that 86% of CBD and 89% of PSP had at least minimal AD neuropathological change.
  • #1 Neuropathology and emerging biomarkers in corticobasal syndrome | Journal of Neurology, Neurosurgery & Psychiatry
    https://jnnp.bmj.com/content/93/9/919
    Although a small subset, it should be recognised that high AD neuropathological change can coexist with CBD and PSP, particularly in elderly individuals. […] Molecular biomarkers that can detect specific pathological proteins hold promise for improved antemortem diagnoses. […] Since several reliable biomarkers for AD have been established, a practical approach is first to differentiate AD from other disorders. […] Amyloid PET has been developed as an imaging biomarker to visualise amyloid accumulation in vivo. […] A meta-analysis of amyloid PET studies reported 23 of 61 (38%) patients with CBS showed amyloid positivity on PET. […] Interestingly, the frequency of amyloid positivity decreases with age. […] As with the interpretation of CSF biomarkers, the possibility of coexisting pathologies other than AD (eg, CBD and PSP) cannot be excluded even in cases where amyloid PET is positive.
  • #1 Neuropathology and emerging biomarkers in corticobasal syndrome | Journal of Neurology, Neurosurgery & Psychiatry
    https://jnnp.bmj.com/content/93/9/919
    Following the success of amyloid PET, tau protein became a target for in vivo molecular diagnosis. […] Tau PET may help distinguish tauopathy-CBS from non-tauopathy-CBS and AD-CBS from non-AD tauopathies; however, it remains challenging to differentiate non-AD-tauopathies, particularly CBD and PSP. […] At present, pathological assessment is required for definitive diagnosis, but in the future, it may be possible to predict the underlying pathology during life based on a combination of clinical symptoms and signs with supporting information from various biomarkers.
  • #1 Neuropathological hints from CSF and serum biomarkers in corticobasal syndrome (CBS): a systematic review | Neurological Research and Practice | Full Text
    https://neurolrespract.biomedcentral.com/articles/10.1186/s42466-023-00294-0
    Additionally, eventual clinical trials would require diagnostic accuracy for the underlying neurodegenerative processes of CBS to deliver the most suitable disease-modifying agents and patient-tailored interventions. […] The present systematic review aimed to investigate the additional value of traditional and cutting-edge CSF and serum/plasma biomarkers in profiling neurodegenerative disorders manifesting with CBS and determine which biomarkers core might be specific and distinctive of CBS. […] Given their informative capacity, future trial designs should consider baseline CSF NfL dosage to stratify treatment arms according to neuropathological substrates, and serum NfL dosage might be used to monitor the evolution of CBS. […] In conclusion, integrating fluid biomarkers, genetic testing, and imaging findings may enhance diagnostic accuracy in routine clinical practice by identifying in vivo the underlying pathological processes, and the neuronal functions more likely to be impaired during disease evolution.
  • #1 Progressive supranuclear palsy & Parkinson’s disease | APDA
    https://www.apdaparkinson.org/article/progressive-supranuclear-palsy-corticobasal-degeneration/
    CBD is less common than PSP, and both are significantly less common than PD. Based on one recent study, the combined number of new cases of PSP and CBD per 100,000 people per year was between 3 and 5. Based on these results, PD is about 5 times more common than these two diseases combined. However these diseases are still seen relatively frequently in Movement disorders clinics and many of our readers are grappling with these conditions. […] Since ageing is the biggest risk factor for APS, the prevalence of PSP and CBD is expected to increase in the coming years. Therefore, there is a pressing need for tests that can diagnose these disorders early and accurately, and treatments that will stop their progression before they become disabling.
  • #1
    https://www.psp.org/iwanttolearn/corticobasal-degeneration
    Corticobasal degeneration (CBD) is a rare neurodegenerative disorder that has no known cause or cure. […] CBD is very rare and there are only 2,000 to 3,000 people diagnosed in the United States. These numbers are likely underestimates because of those who have not yet been accurately diagnosed. […] The average age of symptom onset is in people’s early 60’s, but can begin as early as the 40’s and into the 90’s. Most people with CBD live five to ten years after symptom onset, but many live much longer. There is no clear gender bias in CBD. […] It can take many years for people to receive a CBD diagnosis. This can be because it is often originally misdiagnosed as Parkinson’s diseases because it often begins similarly to Parkinson’s. […] A detailed analysis of the genetics of CBD was published in 2015 by an international group of researchers. […] There is important research being done to look for genetic and environmental contributors to the cause of CBD, as well as research on tests that can lead to more accurate diagnosis and improved care of CBD.
  • #1 Corticobasal Degeneration CBD | Definitions, Symptoms & Advice
    https://www.pspassociation.org.uk/what-is-cbd/
    The diagnosis of CBD is complicated because its symptoms can closely resemble those of other neurological conditions. […] The wide range of symptoms that can develop means that currently, there is no single test that can definitively diagnose CBD. […] The diagnosis of CBD relies on a careful assessment by specialists who are familiar with the range of neurodegenerative diseases. […] The life expectancy of someone living with CBD typically ranges from 5 to 10 years after diagnosis, but it can vary widely depending on individual health factors and the quality of care. […] PSPA plays a pivotal role in supporting individuals and families living with CBD by providing information and support services and advocating for better care and research into the disease. […] Research into CBD is focused on understanding its pathophysiology, improving diagnostic accuracy, and developing effective treatments. […] Researchers are exploring genetic factors that may predispose individuals to CBD, as well as environmental influences that could trigger its onset.
  • #1 SciELO Brazil – Pharmacological interventions in corticobasal degeneration: a review Pharmacological interventions in corticobasal degeneration: a review
    https://www.scielo.br/j/dn/a/H9QPjg9FZdks9zWLsphZdHj/
    Current CBD treatment remains symptomatic and based on data from other similar diseases, such as Parkinson’s disease, AD, and frontotemporal dementia, because of the lack of specific studies on CBD. […] Symptomatic treatment of CBD patients could be useful for improving motor symptoms (parkinsonism, dystonia, myoclonus), but the effects are generally unsatisfactory. In order to handle the behavioral manifestations associated with CBD, we must treat the symptoms that have effective pharmacological interventions, aiming at improving the quality of life of patients.
  • #1 Corticobasal Syndrome (CBS): Causes, Symptoms, Treatment
    https://www.healthline.com/health/parkinsons/corticobasal-syndrome
    No treatment can slow down or reverse the progression of CBS. However, certain drugs can help manage the symptoms. […] Because there’s no treatment for CBS, it will eventually lead to serious complications. […] Because of these complications, people with CBS live an average of 6 to 8 years from the onset of symptoms. […] CBS is a rare neurodegenerative disorder that gradually worsens your physical and cognitive functions. The buildup of a toxic protein in your brain cells called tau causes CBS. […] CBS is very hard to diagnose because no specific test can identify this condition. No treatment exists for this condition, but some drugs and other therapies can help you manage its symptoms. Research on new therapies and diagnostic methods is ongoing, giving hope to people with this condition and their caregivers.
  • #2 Corticobasal Syndrome and Corticobasal Degeneration: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/1150039-overview
    Corticobasal degeneration (CBD), a sporadic neurodegenerative 4-repeat tauopathy, is a pathologically defined entity associated with several clinical phenotypes. The most common phenotype corticobasal syndrome (CBS) is defined by progressive dementia and typically asymmetric parkinsonism unresponsive to dopaminergic therapy, dystonia, limb apraxia, and myoclonus, but these may occur as a result of a number of other pathologic entities. […] Data on incidence and prevalence of corticobasal degeneration (CBD) are still being collected. Clinical reports have multiplied geometrically in the last 20 years, suggesting either that clinical evaluation has become more sensitive (most likely) or that the syndrome is appearing more frequently. It is estimated to account for about 5% of cases of parkinsonism seen in clinics that specialize in movement disorders, or 0.620.92 per 100,000 per year, with an estimated prevalence of 4.97.3 per 100,000.
  • #2 Corticobasal degeneration – Wikipedia
    https://en.wikipedia.org/wiki/Corticobasal_degeneration
    Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. CBD symptoms typically begin in people from 50 to 70 years of age, and typical survival before death is eight years. […] Clinical presentation of CBD usually does not occur until age 60, with the earliest recorded diagnosis and subsequent postmortem verification being age 28. Although men and women present with the disease, some analysis has shown a predominant appearance of CBD in women. Current calculations suggest that the prevalence of CBD is approximately 4.9 to 7.3 per 100,000 people. CBD research has been limited by the rarity of the disease and the lack of research criteria. It is estimated to affect 0.6-0.9 per 100,000 per year. […] Progressive supranuclear palsy (PSP) without CBD is estimated to be ten times more common. CBD represents roughly 46% of patients with Parkinsonism. Average age at disease onset is about 64, with the youngest confirmed onset being at age 43. There may be a slight female predominance.
  • #2 Corticobasal syndrome: a practical guide | Practical Neurology
    https://pn.bmj.com/content/21/4/276
    Corticobasal syndrome is a disorder of movement, cognition and behaviour with several possible underlying pathologies, including corticobasal degeneration. […] It is difficult to ascertain the true prevalence and incidence of corticobasal syndrome, given the varied use of the term and its interchangeability in early reviews with corticobasal degeneration. Estimates are therefore at best a guide and even then, remain crude. The estimated prevalence of corticobasal degeneration is 4.97.3 cases per 100000 population. […] The typical age of presentation is 50s70s and average lifespan from diagnosis to death is 7 years. There does not appear to be any sex bias. […] Identifying corticobasal syndrome carries some prognostic significance, management implications and in the future if protein-based treatments arise may direct further investigations as to underlying pathology.
  • #2
    https://link.springer.com/article/10.1007/s00415-023-11791-2
    Prevalence data on PSP and/or CBS was reported in 23 studies. […] Eight studies (seven papers and one abstract) reported the prevalence of CBS. Reported prevalence figures ranged from 0.77 (0.02-4.32) to 25 (0-59) per 100,000. […] The incidence of PSP/CBS was reported in 12 studies (PSP only n=5, PSP and CBS n=7, no studies with CBS alone), including 11 papers and one abstract. […] The incidence of CBS ranged from 0.03 to 0.8 per 100,000 person-years. […] Data regarding the prevalence and incidence of PSP and CBS are rare, with information on CBS particularly limited. Existing estimates are varied, influenced by study design and size. Evolving diagnostic criteria constitute a particular challenge in the study of these conditions. There is a need for further epidemiological studies, adequately powered to assess the epidemiology of rare diseases, with robust methods of clinical assessment using the most recent diagnostic criteria.
  • #2 Corticobasal Degeneration | Treatment & Management | Point of Care
    https://www.statpearls.com/point-of-care/157387
    Results from a meta-analysis showed the incidence of CBS ranges from 0.03 to 0.8 per 100,000 person-years and its prevalence from 0.83 to 25 per 100,000. […] Additional estimates suggest an annual CBS incidence of less than 1 per 100,000 patients based on study results from Japan and Russia. […] While earlier reports indicated an annual CBD incidence of 0.6 to 0.9 per 100,000, representing 4% to 6% of Parkinsonian syndromes, and a prevalence of 4.9 to 7.3 per 100,000, results from a large United Kingdom cross-sectional study involving 121,608 patients did not identify any confirmed cases of CBD. […] The disease typically has a late onset, with the youngest pathologically confirmed case reported at 42 and an average age of onset around 65. […] An autopsy series from the CurePSP Brain Bank at the Mayo Clinic (Jacksonville, Florida) examined 76 cases of pathologically confirmed CBD. They found a mean age of death of 70 8.7 years (range 46-89 years), with 53% of the cases being men. The estimated average disease duration was 6 2.3 years. […] While results from some studies have suggested a higher prevalence of CBD in women, others have not demonstrated significant sex differences.
  • #2
    https://www.nhs.uk/conditions/corticobasal-degeneration/
    Corticobasal degeneration (CBD) is a rare condition that can cause gradually worsening problems with movement, speech, memory and swallowing. […] Most cases of CBD develop in adults aged between 50 and 70. […] CBD has been linked to changes in certain genes, but these genetic links are weak and the risk to other family members is very low. […] There is currently no treatment that has been shown to stop CBD getting gradually worse, although treatments can reduce many of the symptoms. […] As a result of these complications, the average life expectancy for someone with CBD is around 6 to 8 years from when their symptoms start. However, this is only an average and CBD is very variable.
  • #2
    https://www.psp.org/iwanttolearn/corticobasal-degeneration
    Corticobasal degeneration (CBD) is a rare neurodegenerative disorder that has no known cause or cure. […] CBD is very rare and there are only 2,000 to 3,000 people diagnosed in the United States. These numbers are likely underestimates because of those who have not yet been accurately diagnosed. […] The average age of symptom onset is in people’s early 60’s, but can begin as early as the 40’s and into the 90’s. Most people with CBD live five to ten years after symptom onset, but many live much longer. There is no clear gender bias in CBD. […] It can take many years for people to receive a CBD diagnosis. This can be because it is often originally misdiagnosed as Parkinson’s diseases because it often begins similarly to Parkinson’s. […] A detailed analysis of the genetics of CBD was published in 2015 by an international group of researchers. […] There is important research being done to look for genetic and environmental contributors to the cause of CBD, as well as research on tests that can lead to more accurate diagnosis and improved care of CBD.
  • #2 Corticobasal Syndrome and Corticobasal Degeneration: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/1150039-overview
    In several studies, CBD was reported to be more common in women. However, more recent studies have not found this to be the case. […] Typically, CBD presents between the ages of 50 and 75 years. The CBD cases from multiple brain banks reviewed as part of the Armstrong et al. diagnostic criteria had mean age of onset of 63 years with a standard deviation of 7 years and range of 4577 years. […] This is a progressive neurodegenerative disorder that causes increasing levels of disability and loss of independence. Individuals with CBD usually die within 10 years of symptom onset from complications of dysphagia (aspiration pneumonia), urinary incontinence (urinary tract infections complicated by urosepsis) and an immobile state (susceptibility to infections). […] Prognosis is variable, with several studies indicating mean survival of 68 years from symptom onset; multiple cases with survival of 10 years have been reported.
  • #2 Corticobasal Degeneration (Corticobasal Syndrome): What It Is
    https://my.clevelandclinic.org/health/diseases/22522-corticobasal-degeneration
    Corticobasal degeneration (corticobasal syndrome) is a rare brain condition that causes you to lose your ability to speak, move and remember. Symptoms are progressive, so they slowly get worse over time. While there arent any treatments to slow or stop changes to your brain, therapies are available to help manage the condition. […] Corticobasal degeneration may shorten your life expectancy and lead to life-threatening complications. As symptoms affect more of your body, you may find it difficult to safely maintain your independence. […] Symptoms of corticobasal degeneration typically start between ages 50 and 70. The average onset age is 64. Symptoms may start at age 40, but no reported cases happen before age 40. […] The prognosis (outlook) is poor for corticobasal degeneration. Its a progressive disease, which means itll get worse over time. It usually happens slowly over many years. Your provider will offer treatment options to help you cope and manage symptoms. Treatment options may reduce the severity of symptoms, but it wont stop them from progressing. As symptoms get worse, itll be more challenging to maintain independence and take care of yourself.
  • #2
    https://pspawareness.com/pages/corticobasal-degeneration?srsltid=AfmBOooLje9ENsydQ0j-ahe6jN-FdMNSbl7U8EYh-a8I2D0Gl8ldu6Sg
    Corticobasal Degeneration (CBD) is a rare neurodegenerative disorder often mistaken for Parkinsons Disease (PD. Who It Affects: Onset typically after 60, no strong gender preference. Progression: Declines over 6-8 years, with average life expectancy of 6-8 years post-diagnosis. Not PD: One-sided symptoms and cognitive issues set CBD apart. CBD isnt PDits one-sided symptoms, sensory quirks, and rapid progression demand early recognition. […] Look beyond PDthese subtle signs could reveal CBD and improve care.
  • #2 SciELO Brazil – Pharmacological interventions in corticobasal degeneration: a review Pharmacological interventions in corticobasal degeneration: a review
    https://www.scielo.br/j/dn/a/H9QPjg9FZdks9zWLsphZdHj/
    Corticobasal degeneration (CBD) is a sporadic tauopathy that presents with a varied combination of motor, cognitive, and behavioral features, making its diagnosis difficult. CBD has high morbidity and poor prognosis, with no effective therapy at present. […] CBD presents high morbidity and poor prognosis because of the lack of effective therapy at present. Treatment is symptomatic and based on features of other similar diseases due to the scarcity of studies focused on CBD. […] Given that CBD is correctly diagnosed before death only in 25-56% of cases, discussions about the limitations of safely testing modifying agents are pertinent. Therefore, CBD seems not to spark interest in a greater number of clinical trials due to its low prevalence and the low reliability of clinical diagnosis.
  • #2 Neuropathology and emerging biomarkers in corticobasal syndrome | Journal of Neurology, Neurosurgery & Psychiatry
    https://jnnp.bmj.com/content/93/9/919
    Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and alien limb phenomenon. […] Corticobasal degeneration (CBD) is one of the most common underlying pathologies of CBS, but other disorders, such as progressive supranuclear palsy (PSP), Alzheimers disease (AD) and frontotemporal lobar degeneration with TDP-43 inclusions, are also associated with this syndrome. […] Clinicopathological studies on neurodegenerative disorders associated with CBS have shown that regardless of the underlying pathology, frontoparietal, as well as motor and premotor pathology is associated with CBS. […] Clinical features that can predict the underlying pathology of CBS remain unclear. […] Although the current clinical diagnostic criteria for CBS have suboptimal sensitivity and specificity, emerging biomarkers hold promise for future improvements in the diagnosis of underlying pathology in patients with CBS.
  • #2 Corticobasal degeneration | Radiology Reference Article | Radiopaedia.org
    https://radiopaedia.org/articles/corticobasal-degeneration?embed_domain=external.radpair.com%252527%25255b0%25255d%252527%25255b0%25255dfavicon.icofavicon.icofavicon.icofavicon.icofavicon.ico&lang=gb
    Corticobasal degeneration (CBD) is an uncommon neurodegenerative disease and is one of the subset of tauopathies. […] The vast majority of cases are sporadic, although a number of familial cases have been described. Patients are usually in the fifth to seventh decades of life, with the youngest reported case being 40 years of age.
  • #2 SciELO Brazil – Corticobasal syndrome: A diagnostic conundrum Corticobasal syndrome: A diagnostic conundrum
    https://www.scielo.br/j/dn/a/TMZQJYmKy8NmrSW9FKC9wpf/
    The genetics of cases of CBS is largely unknown and the majority are sporadic. […] There is no specific treatment for CBS, but the ability to accurately detect underlying pathology early in the course of CBS will be crucial when effective therapies are developed. […] Further characterization of the clinical, imaging and neuropsychological hallmarks of CBS patients related to specific pathology is very important, considering the new recent advances in treatment.
  • #3 Corticobasal Degeneration | Treatment & Management | Point of Care
    https://www.statpearls.com/point-of-care/157387
    Corticobasal degeneration (CBD) is a rare and progressive neurodegenerative disorder with diverse clinical and pathological features. The most common clinical presentation, corticobasal syndrome, includes asymmetric limb rigidity, Parkinsonism, dystonia, and cortical dysfunction, such as apraxia or sensory deficits. […] Accurate early diagnosis is essential, as it can guide patient care and facilitate the development of targeted therapies and disease-specific biomarkers. […] CBD is primarily considered an idiopathic or sporadic neurodegenerative disorder, with familial cases being exceedingly rare. […] The only well-established risk factor for CBD is advanced age. […] CBD is a neurodegenerative disorder characterized by complex pathological mechanisms and diverse clinical presentations, collectively referred to as clinicopathologic heterogeneity. This variability significantly hampers antemortem diagnosis and limits the ability to conduct robust epidemiological studies. Notably, CBD pathology is correctly predicted in only 25% to 56% of cases prior to autopsy.
  • #3 Corticobasal Syndrome and Corticobasal Degeneration: Background, Pathophysiology, Epidemiology
    https://emedicine.medscape.com/article/1150039-overview
    Corticobasal degeneration (CBD), a sporadic neurodegenerative 4-repeat tauopathy, is a pathologically defined entity associated with several clinical phenotypes. The most common phenotype corticobasal syndrome (CBS) is defined by progressive dementia and typically asymmetric parkinsonism unresponsive to dopaminergic therapy, dystonia, limb apraxia, and myoclonus, but these may occur as a result of a number of other pathologic entities. […] Data on incidence and prevalence of corticobasal degeneration (CBD) are still being collected. Clinical reports have multiplied geometrically in the last 20 years, suggesting either that clinical evaluation has become more sensitive (most likely) or that the syndrome is appearing more frequently. It is estimated to account for about 5% of cases of parkinsonism seen in clinics that specialize in movement disorders, or 0.620.92 per 100,000 per year, with an estimated prevalence of 4.97.3 per 100,000.
  • #3 Corticobasal syndrome: a type of dementia affecting movement and thinking — DPUK
    https://www.dementiasplatform.uk/news-and-media/blog/corticobasal-syndrome-a-type-of-dementia-affecting-movement-and-thinking
    Corticobasal syndrome (CBS) is a very rare form of dementia, estimated to affect just 5 in every 100,000 people. However, this figure may not be accurate as CBS is often misdiagnosed as a range of other conditions because the varied symptoms overlap with several other diseases. […] CBS is most common in people aged 60-80, and has been seen in people in their 40s, but never in anyone younger that 40.
  • #3 Corticobasal degeneration | MedLink Neurology
    https://www.medlink.com/articles/corticobasal-degeneration
    Corticobasal degeneration is one of the atypical parkinsonian syndromes or parkinsonism-plus syndromes most often characterized by parkinsonism (typically unilateral); apraxia; cortical sensory signs; dystonia; involuntary movements, such as myoclonus; and alien limb sign. […] The rarity of the disease makes epidemiological studies difficult to perform. Disease registries have been used to estimate the prevalence of corticobasal degeneration. It has been reported to be 10 times rarer than a clinicopathologically similar tauopathy, progressive supranuclear palsy. […] There is a mild predominance of men. No geographic predominance or ethnic clustering has been reported.
  • #3 Corticobasal Degeneration (Corticobasal Syndrome): What It Is
    https://my.clevelandclinic.org/health/diseases/22522-corticobasal-degeneration
    On average, many people live between six to eight years after the first symptoms of corticobasal degeneration appear. This isnt the case for everyone, and many people live much longer than this. Your healthcare provider is the best person to talk to about your situation because it may not match statistics.
  • #3 Corticobasal Syndrome (CBS): Causes, Symptoms, Treatment
    https://www.healthline.com/health/parkinsons/corticobasal-syndrome
    No treatment can slow down or reverse the progression of CBS. However, certain drugs can help manage the symptoms. […] Because there’s no treatment for CBS, it will eventually lead to serious complications. […] Because of these complications, people with CBS live an average of 6 to 8 years from the onset of symptoms. […] CBS is a rare neurodegenerative disorder that gradually worsens your physical and cognitive functions. The buildup of a toxic protein in your brain cells called tau causes CBS. […] CBS is very hard to diagnose because no specific test can identify this condition. No treatment exists for this condition, but some drugs and other therapies can help you manage its symptoms. Research on new therapies and diagnostic methods is ongoing, giving hope to people with this condition and their caregivers.
  • #3 Corticobasal Degeneration (CBD) – Brain Support Network
    https://www.brainsupportnetwork.org/education/corticobasal-degeneration/
    The symptoms of these four types are so different that they seem to be entirely different disorders. […] There is remarkably limited treatment for CBD/CBS. The most effective treatments are the therapies: physical therapy, occupational therapy, and speech therapy. Therapies are pinpointed on prevention of falls and aspiration pneumonia. […] The medication that can be prescribed and any other treatments are focused on a few symptoms that may respond to medication or treatments such as depression, urinary incontinence, and dry eyes. There is no evidence that any of the Parkinsons medications (levodopa therapy) or Alzheimers medications are helpful in CBD/CBS. […] The diagnostic criteria listed in this section are derived from the paper Criteria for the diagnosis of corticobasal degeneration, Armstrong, et al. published in Neurology in 2013. […] The paper explains CBD in terms of four distinct types (phenotypes) of the disease. These are: corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), nonfluent/agrammatic variant of primary progressive aphasia (naPPA), progressive supranuclear palsy syndrome (PSPS).
  • #4
    https://www.psp.org/iwanttolearn/corticobasal-degeneration
    Corticobasal degeneration (CBD) is a rare neurodegenerative disorder that has no known cause or cure. […] CBD is very rare and there are only 2,000 to 3,000 people diagnosed in the United States. These numbers are likely underestimates because of those who have not yet been accurately diagnosed. […] The average age of symptom onset is in people’s early 60’s, but can begin as early as the 40’s and into the 90’s. Most people with CBD live five to ten years after symptom onset, but many live much longer. There is no clear gender bias in CBD. […] It can take many years for people to receive a CBD diagnosis. This can be because it is often originally misdiagnosed as Parkinson’s diseases because it often begins similarly to Parkinson’s. […] A detailed analysis of the genetics of CBD was published in 2015 by an international group of researchers. […] There is important research being done to look for genetic and environmental contributors to the cause of CBD, as well as research on tests that can lead to more accurate diagnosis and improved care of CBD.

Zobacz więcej

dysfagia parkinsonizm zespół czołowo-behawioralno-przestrzenny biomarker molekularny autopsja choroba Lewy'ego unieruchomienie zapalenie płuc choroba Picka zakażenie dróg moczowych zatorowość płucna zachorowalność choroba Creutzfeldta-Jakoba choroba naczyniowa mózgu choroba Alzheimera zwyrodnienie korowo-podstawne zachłystowe zapalenie płuc postępujące porażenie nadjądrowe chorobowość tauopatia choroba Parkinsona zespół korowo-podstawny posocznica choroba neuronu ruchowego białko tau otępienie czołowo-skroniowe zaburzenie neurodegeneracyjne nietrzymanie moczu pierwotna postępująca afazja